|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's range||48.31 - 48.91|
|52-week range||39.72 - 51.05|
|Beta (5Y monthly)||0.29|
|PE ratio (TTM)||22.11|
|Forward dividend & yield||1.22 (2.50%)|
|Ex-dividend date||18 Mar 2021|
|1y target est||N/A|
Roche (RHHBY) immuno-oncology drug Tecentriq gets FDA approval for yet another indication of lung cancer.
Atea (AVIR) is developing an oral drug candidate, AT-527, as a potential treatment for COVID-19 in outpatients as well as hospitalized settings in several studies.
Roche (RHHBY) posts an encouraging performance in the third quarter and the first nine months of 2021 driven by demand for coronavirus tests due to the Delta variant and recovery in pharma sales.